Advertisement
Document › Details
Epigenomics AG. (8/30/17). "Press Release: Epigenomics Commences Post Approval Study on Epi proColon". Berlin & Germantown, MD.
Region | United States (USA) | |
Organisation | Epigenomics AG (Frankfurt Prime Standard: ECX, OTCQX: EPGNY) | |
Group | Epigenomics (Group) | |
Organisation 2 | FDA (US Food and Drug Administration) | |
Group | United States (govt) | |
Product | Epi proColon® blood test | |
Product 2 | clinical research | |
Person | Hamilton, Gregory (Greg) (Epigenomics 201607– CEO before AltheaDx + Enigma Diagnostics + Third Wave + Hologic) | |
Person 2 | Bull, David (Epigenomics 201703 Director of Marketing) | |
Epigenomics AG (Frankfurt Prime Standard: ECX, OTCQX: EPGNY), today announced the initiation of a Post Approval Study (PAS), Performance of Epi proColon in Repeated Testing in the Intended Use Population (PERT) - NCT03218423.
The PERT trial is being conducted in concert with the US Food and Drug Administration (FDA) following the 2016 Post Market Approval (PMA) of the blood based Epi proColon screening test for colorectal cancer. Epi proColon is intended for patients who are unwilling or unable to be screened with other methods including colonoscopy and take-home stool tests.
The trial is designed to assess the participation and performance of the Epi proColon test in consecutive years as well as the willingness of patients with a positive Epi proColon test to be referred to colonoscopy. The multi-center PERT trial is initiating at Beaumont Hospital in Royal Oak MI, Geisinger Clinic in Danville PA, West Virginia University in Morgantown WV and three additional centers of excellence within the US. The study will enroll 4,500 subjects over the next three years, with anticipated completion in 2022.
"Epi proColon meets a critical clinical need in the colorectal cancer screening landscape. One in three Americans are still unscreened despite awareness campaigns and sophisticated patient navigation systems. A blood test addresses the typical patient barriers associated with colonoscopy and stool tests," stated Greg Hamilton, CEO of Epigenomics. "This trial will be instrumental in defining the longer-term acceptance and performance of Epi proColon. We are confident that the results will further demonstrate the value of Epi proColon in reaching the millions of eligible Americans that have not yet been screened."
About Epigenomics
Epigenomics is a molecular diagnostics company focused on blood-based detection of cancers using its proprietary DNA methylation biomarker technology. The company develops and commercializes diagnostic products across multiple cancer indications with high medical need. Epigenomics' lead product, Epi proColon, is a blood-based screening test for the detection of colorectal cancer. Epi proColon has received approval from the U.S. Food and Drug Administration (FDA) and is currently marketed in the United States, Europe, and China and selected other countries. Epigenomics' second product, Epi proLung(R), is in development as a blood-based test for lung cancer detection.
For more information, visit www.epigenomics.com.
Contact in the U.S.
David Bull
Director of Marketing
Phone: 240.912.6430
David.Bull@Epigenomics.com
Contact Epigenomics AG
Peter Vogt
Vice President Corporate Communication & Investor Relations
Epigenomics AG
Geneststraße 5
10829 Berlin
Phone +49 (0) 30 24345 386
ir@epigenomics.com
Record changed: 2023-06-05 |
Advertisement
More documents for Epigenomics (Group)
- [1] Epigenomics AG. (7/24/23). "Press Release: Epigenomics AG Announces Successful Agreement on the Acquisition of Significant Assets". Berlin....
- [2] Epigenomics AG. (2/15/23). "Press Release: Epigenomics Decides to Restructure to Minimize Costs". Berlin & San Diego, CA....
- [3] Epigenomics AG. (1/27/23). "Press Release: Resignation of Supervisory Board Chairman Heino von Prondzynski". Berlin....
- [4] InfanDx AG. (8/4/21). "Press Release: Neonatal Diagnostics Company InfanDx AG Appoints Dr. Gunter Weiss as COO". Cologne....
- [5] Epigenomics AG. (10/8/18). "Press Release: Capital Increase through Rights Issue with Subscription Rights of Existing Shareholders [NOT FOR RELEASE, DISTRIBUTION OR PUBLICATION, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES OF AMERICA, CANADA, JAP...
- [6] Epigenomics AG. (8/8/18). "Press Release: Epigenomics AG Announces 2018 Second Quarter and Six Month Financial Results". Berlin & San Diego, CA....
- [7] Epigenomics AG. (7/2/18). "Press Release: Liquid Biopsy Test for Liver Cancer Detection to Obtain CE Mark". Berlin & San Diego, CA....
- [8] Epigenomics AG. (6/11/18). "Press Release: Centers for Medicare & Medicaid Services Publish Preliminary Rate for Epigenomics’ Colorectal Cancer Screening Test Epi proColon". Berlin & Germantown, MD....
- [9] Epigenomics AG. (3/23/18). "Press Release: Epigenomics AG Reports Results for Financial Year 2017". Berlin & Germantown, MD....
- [10] Epigenomics AG. (11/29/17). "Press Release: Supervisory Board of Epigenomics AG Appoints Albert Weber as Executive Vice President Finance and a Member of the Management Board (Vorstand)". Berlin & Germantown, MD....
To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«
Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]
Please visit also our web portals for the European life sciences and the worldwide mass spectrometry industry at Life-Sciences-Europe.com (European life sciences) and Mass-Spec-Capital.com (worldwide mass spectrometry)
Please visit also our web portals for the life sciences in German-speaking Europe (DE, AT & CH) and the worldwide mass spectrometry industry at Life-Sciences-Germany.com (life sciences in German-speaking Europe) and Mass-Spec-Capital.com (worldwide mass spectrometry)
Advertisement
» top